Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics develops investigational therapies for immune-mediated diseases, with news centered on its RASP modulator platform and late-stage ocular programs. Company updates commonly cover reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and next-generation RASP modulators including ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases.
Recurring developments include FDA interactions on the reproxalap New Drug Application, clinical and preclinical results, pipeline prioritization, manufacturing and regulatory disclosures, and research-and-development presentations. Aldeyra also reports conference participation and corporate updates tied to its Nasdaq-listed biotechnology issuer profile.
Aldeyra Therapeutics (ALDX) has achieved the primary endpoint in a Phase 3 clinical trial of reproxalap for dry eye disease. The trial demonstrated statistically superior results for reproxalap over vehicle in reducing ocular discomfort, an FDA-accepted symptom of dry eye disease. This marks the first positive Phase 3 clinical trial in a dry eye chamber with a symptom as a primary endpoint.
The study involved 132 patients, with 66 receiving reproxalap and 66 receiving vehicle. Reproxalap was well-tolerated with no safety concerns. Aldeyra plans to resubmit its New Drug Application (NDA) in 2024, with an expected six-month FDA review period. The company believes these results support reproxalap's potential for rapid clinical effect in reducing ocular discomfort associated with dry eye disease.
Aldeyra Therapeutics (Nasdaq: ALDX) has announced a webcast and conference call scheduled for August 8, 2024, at 9:00 a.m. ET to reveal top-line results from the Phase 3 dry eye disease clinical trial of reproxalap. The company, focused on developing therapies for immune-mediated and metabolic diseases, will provide dial-in numbers for domestic and international callers, with a live audio webcast accessible from their website. Aldeyra's pipeline includes RASP modulators for various systemic and retinal diseases, with reproxalap targeting dry eye disease and allergic conjunctivitis, and ADX-2191 for potential treatment of retinitis pigmentosa.
Aldeyra Therapeutics announced significant advancements in its RASP modulator pipeline and recent preclinical obesity data at its 2024 Investor Roundtable. Key updates include ADX-629 moving to pediatric Phase 2 trials for Sjögren-Larsson Syndrome, with top-line results expected in 2025. ADX-743, showing promising results in lowering triglycerides and fatty acids, is advancing to IND-enabling studies, with an application expected in 2025. ADX-248 will start Phase 1 clinical testing for atopic dermatitis in the second half of 2024. ADX-631 begins preclinical testing for retinal diseases, with an IND application planned for 2025. CEO Todd C. Brady emphasized the expansion of their RASP modulator pipeline for treating inflammatory and metabolic diseases. The Investor Roundtable, including a live webcast, is scheduled for today at 8:00 a.m. ET, with a replay available for 90 days.
Aldeyra Therapeutics (Nasdaq: ALDX) has completed enrollment for its Phase 3 clinical trial of Reproxalap, a topical ocular treatment for dry eye disease. The trial, which enrolled 132 patients, aims to assess ocular discomfort and potentially enable a New Drug Application (NDA) resubmission in the second half of 2024. Previous trials showed statistically significant improvements in ocular discomfort when treated with Reproxalap versus a vehicle. Results are expected in Q3 2024. If successful, this could lead to the first dry eye disease label incorporating clinical data on both chronic symptoms and ocular redness.
Aldeyra Therapeutics (Nasdaq: ALDX) will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024, at 8:00 a.m. ET.
This event will feature remarks from Todd C. Brady, M.D., Ph.D., President and CEO, followed by a Q&A session. Shareholders and prospective investors can submit questions via the webcast portal during the event or ahead of time by email starting Monday, June 17.
The live audio webcast and slide presentation will be accessible on the Aldeyra website, with a replay available for 90 days.
Aldeyra Therapeutics (Nasdaq: ALDX), a clinical-stage biotech firm focused on immune-mediated and metabolic diseases, announced that CEO Todd C. Brady will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event, featuring a discussion with Jefferies' SVP Kelly Shi, is scheduled for 3:30 p.m. ET on June 5, 2024. The company specializes in developing RASP modulators like reproxalap and ADX-2191 for treating conditions such as dry eye disease and retinitis pigmentosa. Webcast details are available on Aldeyra's website, with the session archived for 90 days.
Aldeyra Therapeutics has enrolled the first patient in a Phase 3 clinical trial for reproxalap in treating dry eye disease, aiming for a potential NDA resubmission by the second half of 2024. The company expects positive results to lead to an NDA resubmission to the FDA, incorporating acute and chronic improvements in symptoms and ocular redness. The planned review period for the resubmission is six months, with promising preliminary data from previous trials.
Summary not available.
Summary not available.
Summary not available.